Navigation Links
Patients With OSA at Higher Risk for Cardiovascular Disease

Researchers have found that patients with obstructive sleep apnea (OSA) have higher levels of a type of dead cells (apoptotic cells) from the lining (endothelium) of their blood vessels circulating in their bloodstream than people who do not have OSA. The finding may help explain why those with OSA are at higher risk for cardiovascular disease (CVD).

According to the researchers, levels of apoptotic endothelial cells are correlated with abnormal endothelial vasorelaxation, a precursor of atherosclerosis-related events, and that treatment with nasal continuous positive airway pressure (nasal CPAP) can reduce levels of circulating apoptotic endothelial cells in OSA patients.

These findings appear in the June 1 issue of the American Journal of Respiratory and Critical Care Medicine, a publication of the American Thoracic Society.

Lead researcher Ali El Sohl, M.D., M.P.H., said the study was done to explain why patients with OSA had a higher risk of cardiovascular morbidity and mortality. He added that the increased levels of circulating apoptotic endothelial cells would mean less production of nitric oxide that is crucial to artery vasodilatation. The less nitric oxide, the higher potentially is the risk of hypertension and acute heart attack. CPAP treatment would likely restore the physiologic function of the lining of the blood vessels.

For the study, 14 men with OSA were recruited from the Sleep Clinic at the Erie County Medical Center, a hospital affiliated with the University of Buffalo, in New York. The patients were nonsmokers without any coexisting diseases, and they did not use medications. Ten healthy nonsmokers were recruited from a wellness clinic at the same hospital to serve as controls.

The OSA patients were given polysomnographic testing to verify the diagnosis. This involved evaluating brain waves, electrical activity of muscles, eye movements, breathing rates, blood pressure, blood oxygen saturation and heart rhythm, as well as direct observation of patients during sleep.

The men were comparable in age, blood pressure and metabolic profiles, but the OSA patients had a higher bodymass index, though the difference was not statistically significant. The OSA patients also had more apoptotic cells circulating in their bloodstreams and had vasomotor dysfunction.

The OSA patients were given nasal CPAP treatment for eight weeks. Use of CPAP ranged from four to seven hours per night. At the end of the study, the patients vascular reactivity and circulating endothelial apoptotic cells were reevaluated and compared to the controls.

There were no significant differences in body measurements and metabolism in the men from baseline, but most of the patients who received CPAP had reduced circulating endothelial apoptotic cells and had marked improvements in brachial artery vascular reactivity.

The study had some limitations. Women were excluded to keep the study population homogeneous. Said Dr. El Sohl, a follow-up study would be required to look at this phenomenon in women and in particular the hormonal effect on apoptosis in OSA. The researchers did not perform a thorough assessment for excluding coronary disease.

More research is needed before these results can be applied clinically, according to Dr. El Sohl. While CPAP is currently used to treat OSA, looking for circulating apoptotic endothelial cells as a marker to fine-tune the therapy is one potential application. This may potentially reduce OSA patients risk of CVD. Dr. El Sohl mentioned that statins, angiotensin converting enzyme inhibitors, and vitamin C reduce enthothelial apoptosis, but it is not known if these agents could help patients with OSA.

According to Dr. El Sohl, further research will investigate if the improvements in vascular function correlate with actual improvements in the sleep patterns of patient s with OSA.


'"/>




Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical ... independent supplier of medical equipment, supplies, drugs, vaccines, and ... has entered into an agreement to acquire Vantage Medical ... based in Holtsville, New York . ... in supplying new and emerging medical practices, will operate ...
Breaking Medicine Technology: